As concerns rise about the growing percentage of U.S. drugs manufactured in China, U.S legislators are seeking measures to bring more of the industry back onshore. During a congressional hearing Wednesday, regulators and lawmakers in both parties expressed interest in reducing regulatory hurdles and providing incentives to domestic drug manufacturers to boost production. The U.S., […]

Know more, do more.

You'll get access to all of our original analysis, exclusive features, and more for just $9.